Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health (NYSE:BHC) and its aesthetic business unit Solta Medical have announced a significant milestone for their Thermage technology, surpassing 5 million skin tightening treatments worldwide.
Thermage, a non-invasive treatment system, uses monopolar radiofrequency energy to stimulate collagen production and tighten skin naturally. It is uniquely positioned as the only non-invasive technology approved for upper and lower eyelid treatments.
The company plans to continue investing in research and development while gathering additional clinical evidence to advance the technology further.
Bausch Health (NYSE:BHC) has announced the extension of its tender offer deadline to acquire DURECT Corporation (NASDAQ:DRRX). The offer, originally set to expire on September 9, 2025, has been extended to September 10, 2025, at 5:00 p.m. New York City time.
The all-cash transaction values DURECT at $1.75 per share, with an upfront consideration of approximately $63 million at closing. The deal includes potential additional milestone payments of up to $350 million based on net sales achievements of larsucosterol, contingent on meeting targets before the earlier of 10 years after first U.S. commercial sale or December 31, 2045.
Bausch Health Canada (NYSE:BHC) announced expanded access to its acne treatment CABTREO™ through the public drug plans of Quebec and Saskatchewan. This follows previous coverage announcements in Ontario, Nova Scotia, and federal programs including NIHB, CSC, and Veterans Affairs Canada.
CABTREO is a Canadian-made triple-combination topical prescription for treating acne vulgaris in patients 12 years and older. It is the first and only Health Canada-approved triple-combination treatment combining an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide) in a once-daily topical gel.
Bausch Health (NYSE:BHC) announced significant changes in its shareholding structure and board composition. Paulson Capital Inc. and its affiliates have acquired 34,721,118 common shares previously held by Carl C. Icahn's group, increasing their beneficial ownership to approximately 19.13% of the company's outstanding shares.
Following this transaction, the Director Appointment and Nomination Agreement with the Icahn Group has terminated, leading to the resignation of Brett M. Icahn and Steven D. Miller from the Board of Directors. John A. Paulson, Chairperson of the Bausch Health Board, expressed confidence in the company's value and its efforts to maximize shareholder value.
Bausch Health (NYSE:BHC) has announced the winners of its 2025 Salix Gastrointestinal Health Scholars Program. The company awarded $10,000 scholarships to 10 students living with GI diseases, marking the sixth consecutive year of the program. Selected from over 370 applicants, recipients were chosen across three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parent's Scholar Award.
The scholarship program aims to support students pursuing higher education while managing gastrointestinal conditions. Recipients were selected based on personal essays describing how their GI conditions have influenced their educational journey and the support received from healthcare providers.
Bausch Health (NYSE:BHC) reported strong Q2 2025 financial results with consolidated revenues of $2.53 billion, up 5% year-over-year. The company achieved GAAP Net Income of $148 million and Adjusted EBITDA of $842 million, marking its ninth consecutive quarter of growth.
Key segment performance includes Salix segment growth of 12% driven by Xifaxan®, Solta Medical segment growth of 25%, and Bausch + Lomb segment growth of 5%. The company announced plans to repay approximately $900 million in debt and entered an agreement to acquire DURECT Corporation to expand its hepatology portfolio.
Management reaffirmed its full-year 2025 guidance, projecting consolidated revenues of $10.0-10.25 billion and Adjusted EBITDA of $3.485-3.635 billion.
Bausch Health (NYSE:BHC) has announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX) in a deal valued at approximately $63 million upfront, with potential additional milestone payments of up to $350 million. The acquisition price represents a 217% premium to DURECT's closing price.
The key asset in this acquisition is larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy Designation for treating alcoholic hepatitis (AH). The drug has shown promising results in Phase 2 trials and addresses a significant unmet medical need, as AH accounts for 164,000 hospital admissions in the U.S. annually with no FDA-approved treatments currently available.
The transaction is expected to close in Q3 2025, subject to customary conditions including majority shareholder tender. The deal complements Bausch Health's existing hepatology portfolio, particularly their Phase 3 rifaximin SSD program.
Bausch Health (NYSE:BHC) has announced significant debt reduction initiatives totaling approximately $900 million. The company will redeem $602 million of its 9.25% Senior Notes due 2026 using cash on hand, with the redemption date set for August 28, 2025.
Additionally, Bausch's subsidiary plans to repay $300 million outstanding under its Receivables Facility, with termination scheduled for October 27, 2025. These strategic moves align with the company's objective to optimize its capital structure.
Bausch Health (NYSE:BHC) has expanded its Board of Directors from ten to twelve members with the appointment of two seasoned pharmaceutical industry executives, effective July 22, 2025. Michael Goettler, former CEO of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Sandra Leung, former Executive VP and General Counsel of Bristol Myers Squibb, will join the Nominating and Corporate Governance Committee.
Board Chairman John A. Paulson expressed confidence that their extensive industry experience and leadership capabilities will provide strategic guidance for the company's continued evolution and strengthen its commitment to stakeholders.
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as two federal programs - the Non-Insured Health Benefits (NIHB) for Indigenous populations and the Correctional Service of Canada (CSC).
CABTREO is a first-of-its-kind triple-combination topical prescription treatment for acne vulgaris, approved by Health Canada for patients 12 years and older. The treatment combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel is currently available through most private insurance plans, with plans to expand access through other public drug plans across Canada.